Publications

Publications

Filter Results: (113) Arrow Down

Show Results For

← Page 3 of 113 Results →
  • March 2008
  • Case

Novartis AG: Science-Based Business

By: H. Kent Bowen and Courtney Purrington
Novartis is a science-based drug company, which has important implications for its business strategy. It is one of the largest pharmaceutical companies in the world with over $38B in sales in 2007. Pharmaceuticals account for slightly over $24B of that total. In 2007,... View Details
Keywords: Innovation and Invention; Resource Allocation; Product Development; Partners and Partnerships; Research and Development; Science-Based Business; Pharmaceutical Industry
Related
  • July 2024
  • Case

Gates Ventures: Making Alzheimer's a Forgotten Past

By: Satish Tadikonda, William Marks, Shardule Shah and Calvin Marambo
After a personal journey and interest in Alzheimer's Disease (AD) by Bill Gates, Gates Ventures set out to find the best way to accelerate innovation in the field of AD. In partnership with the Alzheimer's Drug Discovery Foundation, Gates Ventures created the... View Details
Related
  • September 2020
  • Case

Minerva 2010: Turbulent Times

By: John R. Wells and Benjamin Weinstock
In 2010, amid a flurry of new discoveries, Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), raised $6.6 million to test her new cancer drugs in mice. It had been more than 6 years since she had announced that she and her small team at... View Details
Keywords: Biotechnology; Research; Product Development; Commercialization; Strategy
Related
  • 17 Jun 2019
  • Blog Post

Why I Would Have Applied to the MS/MBA Biotechnology: Life Sciences Program

and drug development. These qualities straddle the science and business fields – for example, to instill a science-focused culture within an organization, or to craft a drug development strategy that... View Details
  • 04 Sep 2018
  • First Look

New Research and Ideas, September 4, 2018

moral imperatives, we study the factors that influence when individuals find solutions that fall outside of the salient options presented. In particular, we study moral insight, or the discovery of solutions, other than selecting one of... View Details
Keywords: Dina Gerdeman
  • 25 Mar 2016
  • HBS Seminar

Curtis Keith, Harvard University, Blavatnik Biomedical Accelerator

  • Research Summary

Overview

By: Joshua Lev Krieger
In examining the competitive dynamics of R&D strategy, Josh has become particularly interested in how the introduction of new knowledge generated by rivals impacts the direction of R&D efforts. Understanding how new information alters project portfolio decisions is... View Details
  • Web

Joint Degree Programs - MBA

newest joint degree program, the MS/MBA Biotechnology: Life Sciences, is designed for students interested in growing organizations that will advance new drug discoveries or therapeutics. Learn more MBA... View Details
  • Web

Curriculum - MBA

bedside with an emphasis on translational research. Topics will include in vitro microbial discovery platforms; engineering strategies such as chimeric, humanized, and human Abs; human Fc engineering; and nanobodies, antibody View Details
  • Web

Capstone - MBA

that will advance new drug discoveries and therapeutics with those equally passionate about changing the business of healthcare for the better. 2 The practicalities of business decisions meet the... View Details
  • Web

MS/MBA Biotechnology: Life Sciences - MBA

Biotechnology: Life Sciences Program at Harvard University builds upon students’ existing biotech and life sciences knowledge and equips them with the latest business and scientific insights. This empowers them to lead transformative organizations that will advance new... View Details
  • Web

Overview - MBA

the MS/MBA program, graduates will be able to: Lead science-based organizations, including businesses and non-profits, with an understanding of research culture, relevant timeframes, opportunity-costs, rewards, and organizational behavior. Assess the potential... View Details
  • Web

Faculty & Advisors - MBA

valued at over $12 billion. At Underscore VC, she invested in fast growing B2B software startups, including life sciences tech products used by leading biopharma companies across the drug development cycle from R&D to commercial stages.... View Details
  • Web

FAQs - MBA

biotechnology or pharmaceutical companies, who go deep into the specifics of fundamental papers and clinical trials, and thereby provide students with approaches, background, and tools that they can bring in their subsequent careers in View Details
  • Web

Blavatnik Fellowship in Life Science Entrepreneurship - Health Care

Driven by personal and family experiences, Andrew is dedicated to advancing brain-related medicines. As a fellow, Andrew will be growing Modulate Bio’s drug discovery platform, focused on developing novel... View Details
  • Web

Degrees, Certifications & Alumni Status | About

grow transformative organizations that will advance new drug discoveries or therapeutics. The MS/MBA: Engineering Sciences Program Grants : Master in Business Administration from Harvard Business School... View Details
  • Web

Curriculum - MBA

More Field Course: Entrepreneurial Sales & Marketing Startups face challenges with customer acquisition at stages from customer discovery to scaling. This course examines some representative issues and tools for that context. Read More... View Details
  • Web

Fostering Innovation in Life Sciences - Health Care

the vibrant entrepreneurial community at Harvard. GETTING LIFE-SAVING DRUGS TO MARKET is a research focus for Professor Amitabh Chandra . He examines the unique effects that economics and market factors have on the development of... View Details
  • 26 Aug 2024
  • Blog Post

HBS Lingo 101

Program. Graduates earn two degrees in two years and are prepared to grow transformative organizations that will advance new drug discoveries or therapeutics. HIVES: Classrooms in Batten Hall designed with... View Details
  • 01 Jun 2024
  • News

Quantum Leap

day quantum computing becomes a reality is the day conventional digital security ends.) They should even be able to do things that digital computers cannot do at all, like realistically modeling molecules for more efficient drug View Details
Keywords: Alexander Gelfand; photographed by Chris Sorensen; quantum computing; innovation; leadership; Computer and Electronic Product Manufacturing; Manufacturing